secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117256
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q3 2022 cash $50.5M; FDA clears Phase 2 trial for VCN-01 in PDAC
--------------------------------------------------------------------------------

- Cash and cash equivalents $50.5M as of Sep 30, 2022; expected runway into Q1 2024.
- FDA and AEMPS cleared the planned Phase 2 trial of VCN-01 in pancreatic ductal adenocarcinoma patients.
- SYN-004 Phase 1b/2a in allo-HCT: positive DSMC review for Cohort 1; first patient dosed in Cohort 2 (Oct 2022).
- Company rebranded as Theriva Biologics and began trading under ticker TOVX on NYSE American in October 2022.
- Anticipated near-term milestones: initiate VIRAGE Phase 2 for VCN-01 in PDAC Q4 2022; pre-IND meeting for retinoblastoma early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/0001104659-22-117256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465922117256/tm2230285d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer